SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection.
Mijnes J, Tiedemann J, Eschenbruch J, Gasthaus J, Bringezu S, Bauerschlag D, Maass N, Arnold N, Weimer J, Anzeneder T, Fasching PA, Rübner M, Bruno B, Heindrichs U, Freres J, Schulz H, Hilgers RD, Ortiz-Brüchle N, von Serenyi S, Knüchel R, Kloten V, Dahl E.
Oncotarget. 2019 Nov 5;10(60):6494-6508. doi: 10.18632/oncotarget.27303.


[Status of the availability and use of next generation sequencing (NGS) in bladder cancer-a questionnaire within the uropathology working group].
Ortiz-Brüchle N, Muders M, Toma M, Esposito I, Hartmann A, Stöhr R, Reis H, Wild P, Köllermann J, Bremmer F, Leichsenring J, Stenzinger A, Merkelbach-Bruse S, Kirfel S, Perner S, Hartmann N, Roth W, Jung A, Kirchner T, Schwamborn K, Pfarr N, Dahl E, Knüchel R, Gaisa NT.
Urologe A. 2019 Sep 20. doi: 10.1007/s00120-019-01046-2.

[Liquid biopsy in human non-small-cell lung cancer : Blood-based analysis of ctDNA methylation].
Schulz H, Tator M, Spillner J, Dreher M, Knüchel-Clarke R, Kloten V, Dahl E.
Pathologe. 2018 Dec;39 (Suppl 2):193-198. doi: 10.1007/s00292-018-0536-5.


[Biobanking and the further development of precision medicine].
Dahl E.
Pathologe. 2018 Jun 6. doi: 10.1007/s00292-018-0449-3. Review. German.


[Biobanks : A central task in pathology].
Dahl E, Schirmacher P, Knüchel-Clarke R.
Pathologe. 2018 May 30. doi: 10.1007/s00292-018-0448-4.


Promoter methylation of DNA damage repair (DDR) genes in human tumor entities: RBBP8/CtIP is almost exclusively methylated in bladder cancer.
Mijnes J, Veeck J, Gaisa NT, Burghardt E, de Ruijter TC, Gostek S, Dahl E, Pfister D, Schmid SC, Knüchel R, Rose M.
Clin Epigenetics. 2018 Feb 6;10:15. doi:10.1186/s13148-018-0447-6.


ITIH5 induces a shift in TGF-β superfamily signaling involving Endoglin and reduces risk for breast cancer metastasis and tumor death.
Rose M, Meurer SK, Kloten V, Weiskirchen R, Denecke B, Antonopoulos W, Deckert M, Knüchel R, Dahl E.
Mol Carcinog. 2018 Feb;57(2):167-181. doi: 10.1002/mc.22742.

Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network.
Koensgen D, Stope MB, Tuerbachova I, Bruennert D, Kohlmann T, Braicu I, Sehouli J, Denkert C, Darb-Esfahani S, Stickeler E, Sofroni D, Dahl E, Mustea A.
Gynecol Obstet Invest. 2017 Jul 22. doi: 10.1159/000479027. [Epub ahead of print]


Oncogenic features of neuromedin U in breast cancer are associated with NMUR2 expression involving crosstalk with members of the WNT signaling pathway.
Garczyk S, Klotz N, Szczepanski S, Denecke B, Antonopoulos W, von Stillfried S, Knüchel R, Rose M, Dahl E.
Oncotarget. 2017 May 30;8(22):36246-36265. doi: 10.18632/oncotarget.16121.


ITIH5 mediates epigenetic reprogramming of breast cancer cells.
Rose M, Kloten V, Noetzel E, Gola L, Ehling J, Heide T, Meurer SK, Gaiko-Shcherbak A, Sechi AS, Huth S, Weiskirchen R, Klaas O, Antonopoulos W, Lin Q, Wagner W, Veeck J, Gremse F, Steitz J, Knüchel R, Dahl E.
Mol Cancer. 2017 Feb 23;16(1):44. doi: 10.1186/s12943-017-0610-2.


Gene expression analysis combined with functional genomics approach identifies ITIH5 as tumor suppressor gene in cervical carcinogenesis.
Dittmann J, Ziegfeld A, Jansen L, Gajda M, Kloten V, Dahl E, Runnebaum IB, Dürst M, Backsch C.
Mol Carcinog. 2017 Jun;56(6):1578-1589. doi: 10.1002/mc.22613. Epub 2017 Mar 6.


Liquid biopsy in colon cancer: comparison of different circulating DNA extraction systems following absolute quantification of KRAS mutations using Intplex allele-specific PCR.
Kloten V, Rüchel N, Brüchle NO, Gasthaus J, Freudenmacher N, Steib F, Mijnes J, Eschenbruch J, Binnebösel M, Knüchel R, Dahl E.
Oncotarget. 2017 8:86253-86263. doi: 10.18632/oncotarget.21134.

Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.
Schlensog M, Magnus L, Heide T, Eschenbruch J, Steib F, Tator M, Kloten V, Rose M, Noetzel E, Gaisa NT, Knüchel R, Dahl E.
Epigenetics. 2016 Sep 13:0. doi: 10.1080/15592294.2016.1229730. [Epub ahead of print]


Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients.
Dietz S, Schirmer U, Mercé C, von Bubnoff N, Dahl E, Meister M, Muley T, Thomas M, Sültmann H.
PLoS One. 2016 Aug 16;11(8):e0161012. doi: 10.1371/journal.pone.0161012. eCollection 2016.


Loss of Dickkopf 3 Promotes the Tumorigenesis of Basal Breast Cancer.
Lorsy E, Topuz AS, Geisler C, Stahl S, Garczyk S, von Stillfried S, Hoss M, Gluz O, Hartmann A, Knüchel R, Dahl E.
PLoS One. 2016 Jul 28;11(7):e0160077. doi: 10.1371/journal.pone.0160077. eCollection 2016.


Abundant NDRG2 Expression Is Associated with Aggressiveness and Unfavorable Patients' Outcome in Basal-Like Breast Cancer.
Kloten V, Schlensog M, Eschenbruch J, Gasthaus J, Tiedemann J, Mijnes J, Heide T, Braunschweig T, Knüchel R, Dahl E.
PLoS One. 2016 Jul 11;11(7):e0159073. doi: 10.1371/journal.pone.0159073. eCollection 2016.


The atypical cadherin Dachsous1 localizes to the base of the ciliary apparatus in airway epithelia.
Dau C, Fliegauf M, Omran H, Schlensog M, Dahl E, van Roeyen CR, Kriz W, Moeller MJ, Braun GS.
Biochem Biophys Res Commun. 2016 May 13;473(4):1177-1184. doi: 10.1016/j.bbrc.2016.04.036. Epub 2016 Apr 10.

[Liquid biopsy analysis using cell-free DNA (cfDNA): Opportunities and limitations].
Dahl E, Kloten V.
Pathologe. 2015 Nov;36(6):572-8. doi: 10.1007/s00292-015-0078-z. Review. German.


Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.
Dötsch MM, Kloten V, Schlensog M, Heide T, Braunschweig T, Veeck J, Petersen I, Knüchel R, Dahl E.
Epigenetics. 2015;10(10):903-12. doi: 10.1080/15592294.2015.1078049. Epub 2015 Aug 7.


Towards sustainable data management in professional biobanking.
Leusmann P, Veeck J, Jäkel J, Dahl E, Knüchel-Clarke R, Spreckelsen C.
Stud Health Technol Inform. 2015;212:94-102.


AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection.
Garczyk S, von Stillfried S, Antonopoulos W, Hartmann A, Schrauder MG, Fasching PA, Anzeneder T, Tannapfel A, Ergönenc Y, Knüchel R, Rose M, Dahl E.
PLoS One. 2015 Apr 15;10(4):e0122106. doi: 10.1371/journal.pone.0122106. eCollection 2015.


Inter-α-trypsin inhibitor heavy chain 5 (ITIH5) is overexpressed in inflammatory skin diseases and affects epidermal morphology in constitutive knockout mice and murine 3D skin models.
Huth S, Heise R, Vetter-Kauczok CS, Skazik C, Marquardt Y, Czaja K, Knüchel R, Merk HF, Dahl E, Baron JM.
Exp Dermatol. 2015 Sep;24(9):663-8. doi: 10.1111/exd.12704. Epub 2015 Apr 17.

OASIS/CREB3L1 is epigenetically silenced in human bladder cancer facilitating tumor cell spreading and migration in vitro.
Rose M, Schubert C, Dierichs L, Gaisa NT, Heer M, Heidenreich A, Knüchel R, Dahl E.
Epigenetics. 2014 Dec;9(12):1626-40. doi: 10.4161/15592294.2014.988052.


[Chances and risks of blood-based molecular pathological analysis of circulating tumor cells (CTC) and cell-free DNA (cfDNA) in personalized cancer therapy: positional paper from the study group on liquid biopsy of the working group for molecular pathology in the German Society of Pathology (DGP)].
Dahl E, Jung A, Fassunke J, Hummel M, Penzel R, Dietmaier W, Laßmann S.
Pathologe. 2015 Feb;36(1):92-7. doi: 10.1007/s00292-014-2069-x. Review. German. No abstract available.


Epigenetic inactivation of ST6GAL1 in human bladder cancer.
Antony P, Rose M, Heidenreich A, Knüchel R, Gaisa NT, Dahl E.
BMC Cancer. 2014 Dec 2;14:901. doi: 10.1186/1471-2407-14-901.


[Report of the working group on molecular pathology 2014].
Dietmaier W, Merkelbach-Bruse S, Dahl E.
Pathologe. 2014 Nov;35 Suppl 2:298-9. doi: 10.1007/s00292-014-1981-4. German. No abstract available.


Epigenetic inactivation of the novel candidate tumor suppressor gene ITIH5 in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype.
Kloten V, Rose M, Kaspar S, von Stillfried S, Knüchel R, Dahl E.
Epigenetics. 2014 Sep;9(9):1290-301. doi: 10.4161/epi.32089. Epub 2014 Aug 4.


BDNF is associated with SFRP1 expression in luminal and basal-like breast cancer cell lines and primary breast cancer tissues: a novel role in tumor suppression?
Huth L, Rose M, Kloubert V, Winkens W, Schlensog M, Hartmann A, Knüchel R, Dahl E.
PLoS One. 2014 Jul 18;9(7):e102558. doi: 10.1371/journal.pone.0102558. eCollection 2014.


Loss of anterior gradient-2 expression is an independent prognostic factor in colorectal carcinomas.
Riener MO, Thiesler T, Hellerbrand C, Amann T, Cathomas G, Fritzsche FR, Dahl E, Bahra M, Weichert W, Terracciano L, Kristiansen G.
Eur J Cancer. 2014 Jul;50(10):1722-30. doi: 10.1016/j.ejca.2014.04.012. Epub 2014 Apr 30.


Molecular Diagnostic Applications in Colorectal Cancer.
Huth L, Jäkel J, Dahl E.
Microarrays (Basel). 2014 Jun 26;3(3):168-79. doi: 10.3390/microarrays3030168. Review.


Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours.
Rose M, Gaisa NT, Antony P, Fiedler D, Heidenreich A, Otto W, Denzinger S, Bertz S, Hartmann A, Karl A, Knüchel R, Dahl E. 
Carcinogenesis. 2014 Mar;35(3):727-36.

[Personalized urooncology based on molecular uropathology: what is the future?].
Dahl E, Haller F.
Urologe A. 2013 Jul;52(7):976-81. doi: 10.1007/s00120-013-3229-y. German.


Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening.
Kloten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, Veeck J, Hartmann A, Knüchel R, Dahl E.
Breast Cancer Res. 2013 Jan 15;15(1):R4. doi: 10.1186/bcr3375.

Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemia.
Oing C, Jost E, Dahl E, Wilop S, Brümmendorf TH, Galm O.
Clin Epigenetics. 2011 Aug;2(2):419-23.

Endogenous myoglobin in breast cancer is hypoxia-inducible by alternative transcription and functions to impair mitochondrial activity: a role in tumor suppression?
Kristiansen G, Hu J, Wichmann D, Stiehl DP, Rose M, Gerhardt J, Bohnert A, ten Haaf A, Moch H, Raleigh J, Varia MA, Subarsky P, Scandurra FM, Gnaiger E, Gleixner E, Bicker A, Gassmann M, Hankeln T, Dahl E, Gorr TA.
J Biol Chem. 2011 Dec 16;286(50):43417-28.

Paradox of sonic hedgehog (SHH) transcriptional regulation: Alternative transcription initiation overrides the effect of downstream promoter DNA methylation.
ten Haaf A, Franken L, Heymann C, von Serenyi S, Cornelissen C, de Hoon JP, Veeck J, Lüscher B, Knüchel R, Dahl E.
Epigenetics. 2011 Apr;6(4):465-77.

Noetzel E, Rose M, Sevinc E, Hilgers RD, Hartmann A, Naami A, Knüchel R, Dahl E. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse. Oncogene. 2010 29:4814-25.



Kristiansen G, Rose M, Geisler C, Fritzsche FR, Gerhardt J, Lüke C, Ladhoff AM, Knüchel R, Dietel M, Moch H, Varga Z, Theurillat JP, Gorr TA, Dahl E. Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype. Br J Cancer. 2010 102:1736-45.



Veeck J, Dahl E. RNA expression analysis on formalin-fixed paraffin-embedded tissues in TMA format by RNA in situ hybridization. Methods Mol Biol. 2010 664:135-50.



Antony P, Rose M, Gaisa NT, Alkaya S, Heidenreich A, Knüchel R, Dahl E. Characterisation of DNA methylation biomarkers for bladder cancer. Pathologe. 2010 Aug 28. [Epub ahead of print] German.



Koensgen D, Freitag C, Klaman I, Dahl E, Mustea A, Chekerov R, Braicu I, Lichtenegger W, Sehouli J. Expression and localization of e-cadherin in epithelial ovarian cancer. Anticancer Res. 2010 7:2525-30.



Knüchel-Clarke R, Dahl E, Gaisa NT, Schwamborn K, Lindemann-Docter K, Henkel C.

Current knowledge in molecular pathology of urothelial cancer. Pathologe. 2010 Jul 29. [Epub ahead of print] German.



Raman S, Fuchs TJ, Wild PJ, Dahl E, Buhmann JM, Roth V.

Infinite mixture-of-experts model for sparse survival regression with application to breast cancer.


Dahl E, En-Nia A, Wiesmann F, Krings R, Djudjaj S, Breuer E, Fuchs T, Wild PJ, Hartmann A, Dunn SE, Mertens PR. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. BMC Cancer. 2009 9:410. * (Highly accessed)



ten Haaf A, Bektas N, von Serenyi S, Losen I, Arweiler EC, Hartmann A, Knüchel R, Dahl E. Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival. BMC Cancer. 2009 9:298. * (Highly accessed)



Verjans E, Noetzel E, Bektas N, Schütz AK, Lue H, Lennartz B, Hartmann A, Dahl E, Bernhagen J. Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer. 2009 9:230. * (Highly accessed)



Veeck J, Wild PJ, Fuchs T, Schüffler PJ, Hartmann A, Knüchel R, Dahl E. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer. 2009 9:217. * (Highly accessed)



Jörissen H, Bektas N, Dahl E, Hartmann A, ten Haaf A, Di Fiore S, Kiefer H, Thess A, Barth S, Klockenbring T. Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer. Jörissen H, Bektas N, Dahl E, Hartmann A, ten Haaf A, Di Fiore S, Kiefer H, Thess A, Barth S, Klockenbring T. BMC Cancer. 2009 9:200. * (Highly accessed)



Wiesmann F, Veeck J, Galm O, Hartmann A, Esteller M, Knüchel R, Dahl E. Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer. Breast Cancer Res. 2009 11:R34.



Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, Scholten D, Berres ML, Zimmermann H, Streetz KL, Tacke F, Hillebrandt S, Schmitz P, Keppeler H, Berg T, Dahl E, Gassler N, Friedman SL, Trautwein C. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology. 2009 137:309-19.



Sadr-Nabavi A, Ramser J, Volkmann J, Naehrig J, Wiesmann F, Betz B, Hellebrand H, Engert S, Seitz S, Kreutzfeld R, Sasaki T, Arnold N, Schmutzler R, Kiechle M, Niederacher D, Harbeck N, Dahl E, Meindl A. Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer. 2009 124:1727-35.



Raman S, Fuchs TJ, Wild PJ, Dahl E, Roth V. The Bayesian Group-Lasso for Analyzing Contingency Tables. ACM International Conference Proceeding Series; Vol. 382 archive



Proceedings of the 26th Annual International Conference on Machine Learning. Montreal, Quebec, Canada. Pages: 881-888. Year of Publication: 2009. ISBN:978-1-60558-516-1

Link zu dem Paper: